Who Generates Higher Gross Profit? Gilead Sciences, Inc. or BioMarin Pharmaceutical Inc.

Gilead Sciences vs. BioMarin Pharmaceutical: A Decade of Gross Profit Analysis

In the competitive landscape of the pharmaceutical industry, Gilead Sciences, Inc. and BioMarin Pharmaceutical Inc. have been key players. Over the past decade, from 2014 to 2023, Gilead Sciences consistently outperformed BioMarin in terms of gross profit. Gilead's gross profit peaked in 2015 at approximately $28.6 billion, showcasing its dominance with nearly 10 times the profit of BioMarin in the same year. Despite fluctuations, Gilead maintained a robust average gross profit of around $21.6 billion annually.

BioMarin, on the other hand, demonstrated steady growth, with its gross profit increasing by nearly 200% from 2014 to 2023. By 2023, BioMarin's gross profit reached approximately $1.8 billion, reflecting its strategic advancements in niche markets. This analysis highlights the contrasting strategies and market positions of these two pharmaceutical giants, offering insights into their financial trajectories over the years.